Latest News

  • Alkermes Receives FDA Complete Response Letter Related to ALKS 3831 Manufacturing Records Review Read More
  • Alkermes Presents New Data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting Read More
  • Alkermes Reschedules Third Quarter 2020 Financial Results Conference Call to 10:30 a.m. ET Read More
  • Alkermes plc Reports Third Quarter 2020 Financial Results and Raises 2020 Financial Expectations Read More

Investors

Response to Current Events